Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX)
CUSIP: 45720N103
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 14,560,641
- Total 13F shares
- 12,777,955
- Share change
- +2,191,004
- Total reported value
- $1,009,450,047
- Put/Call ratio
- 69%
- Price per share
- $79.00
- Number of holders
- 138
- Value change
- +$184,334,509
- Number of buys
- 80
- Number of sells
- 46
Quarterly Holders Quick Answers
What is CUSIP 45720N103?
CUSIP 45720N103 identifies INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 45720N103:
Top shareholders of INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13D/G
3/4/5
13F
|
10%+ Owner · Company |
10%
|
1,454,608
|
$106,593,674 | $0 | 31 Dec 2025 | |
| MORGAN STANLEY |
13D/G
13F
|
Company |
7.9%
|
1,155,416
|
$84,668,884 | $0 | 31 Dec 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
5.3%
|
768,130
|
$60,682,270 | +$6,933,198 | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
9.1%
|
1,327,707
|
$44,717,171 | — | 30 Sep 2025 | |
| Sanofi |
13F
|
Company |
8%
|
1,157,926
|
$38,998,948 | — | 30 Sep 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
6%
|
871,759
|
$29,360,843 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
594,918
|
$20,036,838 | — | 30 Sep 2025 | |
| Mark P. Lappe |
3/4/5
13D/G
|
Chief Executive Officer, Director · Mark Lappe |
6.4%
from 13D/G
|
1,225,413
mixed-class rows
|
$15,852,324 | — | 12 Sep 2024 | |
| Jon Faiz Kayyem |
3/4/5
13D/G
|
Director |
7.9%
from 13D/G
|
1,074,046
mixed-class rows
|
$15,030,087 | — | 28 May 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
3%
|
440,092
|
$14,822,299 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
2.3%
|
336,590
|
$11,336,351 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2%
|
297,820
|
$10,030,578 | — | 30 Sep 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
1.6%
|
239,644
|
$8,071,210 | — | 30 Sep 2025 | |
| Caligan Partners LP |
13F
|
Company |
1.6%
|
236,383
|
$7,961,379 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
221,920
|
$7,476,072 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.4%
|
203,923
|
$6,868,127 | — | 30 Sep 2025 | |
| Brendan P. Eckelman |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
648,888
mixed-class rows
|
$6,127,372 | — | 29 May 2024 | |
| READYSTATE ASSET MANAGEMENT LP |
13F
|
Company |
1.2%
|
170,158
|
$5,730,921 | — | 30 Sep 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.1%
|
161,909
|
$5,453,095 | — | 30 Sep 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.67%
|
97,382
|
$3,279,825 | — | 30 Sep 2025 | |
| Douglas G. Forsyth |
3/4/5
|
Director |
—
mixed-class rows
|
239,564
mixed-class rows
|
$3,159,615 | — | 28 May 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.64%
|
92,657
|
$3,120,688 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.54%
|
78,812
|
$2,654,388 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.43%
|
62,941
|
$2,119,853 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.39%
|
57,194
|
$1,926,294 | — | 30 Sep 2025 | |
| SummitTX Capital, L.P. |
13F
|
Company |
0.37%
|
54,143
|
$1,823,536 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.34%
|
50,125
|
$1,688,210 | — | 30 Sep 2025 | |
| Groupe la Francaise |
13F
|
Individual |
0.33%
|
47,334
|
$1,594,209 | — | 30 Sep 2025 | |
| Slotnik Capital, LLC |
13F
|
Company |
0.28%
|
41,401
|
$1,394,386 | — | 30 Sep 2025 | |
| Laird Norton Wetherby Wealth Management, LLC |
13F
|
Company |
0.28%
|
40,656
|
$1,369,295 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
0.27%
|
39,327
|
$1,324,521 | — | 30 Sep 2025 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.26%
|
38,134
|
$1,284,352 | — | 30 Sep 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.24%
|
35,176
|
$1,184,728 | — | 30 Sep 2025 | |
| Birchview Capital, LP |
13F
|
Company |
0.22%
|
31,698
|
$1,067,589 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.2%
|
29,759
|
$1,002,282 | — | 30 Sep 2025 | |
| CREDIT INDUSTRIEL ET COMMERCIAL |
13F
|
Individual |
0.2%
|
28,958
|
$975,305 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.2%
|
28,445
|
$957,000 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.19%
|
27,793
|
$936,068 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.19%
|
27,242
|
$917,511 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.18%
|
25,966
|
$874,535 | — | 30 Sep 2025 | |
| Meridian Wealth Advisors, LLC |
13F
|
Company |
0.17%
|
25,000
|
$842,000 | — | 30 Sep 2025 | |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management |
13F
|
Company |
0.16%
|
22,584
|
$760,630 | — | 30 Sep 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.13%
|
19,230
|
$647,666 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.12%
|
17,832
|
$600,581 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.12%
|
17,584
|
$592,229 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.12%
|
17,574
|
$591,892 | — | 30 Sep 2025 | |
| Mariner, LLC |
13F
|
Company |
0.12%
|
17,342
|
$584,079 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.12%
|
17,164
|
$578,084 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
16,500
|
$555,720 | — | 30 Sep 2025 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.11%
|
16,377
|
$551,577 | — | 30 Sep 2025 |
Institutional Holders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) as of Q4 2025
As of 31 Dec 2025,
Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) was held by
138 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,777,955 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, VIKING GLOBAL INVESTORS LP, MORGAN STANLEY, Sanofi, HighTower Advisors, LLC, BlackRock, Inc., VANGUARD GROUP INC, Sofinnova Investments, Inc., Capital Research Global Investors, and STATE STREET CORP.
This page lists
138
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
101
Q4 2025 holders
138
Holder diff
37
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.